Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Helen W Sullivan"'
Autor:
Kristen Giombi, Catherine Viator, Juliana Hoover, Janice Tzeng, Helen W Sullivan, Amie C O'Donoghue, Brian G Southwell, Leila C Kahwati
Publikováno v:
PLoS ONE, Vol 17, Iss 2, p e0263339 (2022)
We conducted a scoping systematic review with respect to how consumer engagement with interactive advertising is evaluated and if interactive features influence consumer recall, awareness, or comprehension of product claims and risk disclosures for i
Externí odkaz:
https://doaj.org/article/e130f0b90cd245958d2bea90e1fa7a4d
Autor:
Caroline Rains, Kathryn J. Aikin, Helen W. Sullivan, Bridget J. Kelly, Shirley Liu, Camara Wooten, Jenna Brophy, Susana Peinado, Lauren McCormack, Sandra Crouse Quinn
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-16 (2024)
Abstract Background Under Sect. 564 of the Federal Food, Drug, and Cosmetic Act, when the US Department of Health and Human Services Secretary issues a declaration based on one of four types of determinations, FDA may authorize an unapproved product
Externí odkaz:
https://doaj.org/article/f391605836bd4c0cba8053bc5a16132d
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155035 (2016)
The volume of prescription drug promotion over time is often measured by assessing changes in ad spending. However, this method obscures the fact that some types of advertising are more expensive than others. Another way to measure the changes in pre
Externí odkaz:
https://doaj.org/article/4c5378f68a9046218187799bfb3633e7
Autor:
Kristen Giombi, Jessica Thompson, Candi Wines, Ryan Haughney, Helen W. Sullivan, Kevin R. Betts
Publikováno v:
Research in Social and Administrative Pharmacy. 19:859-872
Autor:
Kathryn J. Aikin, Helen W. Sullivan, Andrew Caporaso, Victoria Hoverman, Ting Yan, Douglas Williams, Jennifer Crafts
Publikováno v:
Pharmacoepidemiology and Drug Safety. 32:312-320
FDA regulations state print ads for prescription drugs must provide a true statement of information "in brief summary" describing "side effects, contraindications and effectiveness." To fulfill these requirements, these ads typically display risk inf
Autor:
Helen W Sullivan, Amie C O’Donoghue, Vanessa Boudewyns, Ryan S Paquin, Kate Ferriola-Bruckenstein
Publikováno v:
Oncologist
Background This study examined how people interpret overall survival (OS), overall response rate (ORR), and progression-free survival (PFS) endpoints in the context of direct-to-consumer television ads. Although there is little research on this topic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf2598f790d7daf8bfd6af32df21599
https://europepmc.org/articles/PMC10322139/
https://europepmc.org/articles/PMC10322139/
Autor:
Jessica Thompson, Molly Lynch, Helen W. Sullivan, Kathryn J. Aikin, Suzanne Dolina, Micaela Brewington
Publikováno v:
Therapeutic Innovation & Regulatory Science.
Publikováno v:
Research in socialadministrative pharmacy : RSAP. 18(12)
Character-space-limited (CSL) communications (e.g., tweets) present a challenge for maintaining fair balance between risks and benefits in direct-to-consumer prescription drug promotion. Current FDA guidance advises incorporating risk information wit
Lay Representations of Cancer Prevention and Early Detection: Associations With Prevention Behaviors
Autor:
Helen W. Sullivan, PhD, MPH, Lila J. Finney Rutten, PhD, MPH, Bradford W. Hesse, PhD, Richard P. Moser, PhD, Alexander J. Rothman, PhD, Kevin D. McCaul, PhD
Publikováno v:
Preventing Chronic Disease, Vol 7, Iss 1 (2010)
IntroductionThe Common Sense Model of illness representations posits that how people think about an illness affects how they try to prevent the illness. The purpose of this study was to determine whether prevention representations vary by cancer type
Externí odkaz:
https://doaj.org/article/ca6f36aaa8b34b6c9d2bc39ee9083f08
Autor:
Suzanne L, West, Linda B, Squiers, Lauren, McCormack, Brian G, Southwell, Emily S, Brouwer, Mahima, Ashok, Linda, Lux, Vanessa, Boudewyns, Amie, O'Donoghue, Helen W, Sullivan
Publikováno v:
Pharmacoepidemiology and drug safety. 22(5)
Under the Food, Drug, and Cosmetic Act, all promotional materials for prescription drugs must strike a fair balance in presentation of risks and benefits. How to best present this information is not clear. We sought to determine if the presentation o